Caribou Biosciences (CRBU) Stock News

Caribou Biosciences (CRBU) reported significant progress in its clinical pipeline and a strong financial position with $366.1 million in cash as of June 30, 2022. The company achieved a 100% complete response rate in its CB-010 ANTLER Phase 1 trial for relapsed or refractory B cell non-Hodgkin lymphoma. Plans include enrolling more patients and submitting IND applications for CB-011 and CB-012 in late 2022 and 2023, respectively. Revenue from licensing and collaborations increased significantly, but R&D and G&A expenses also rose, leading to a net loss of $26.7 million for Q2 2022.

Caribou Biosciences (CRBU) reported promising results from its ANTLER Phase 1 trial for CB-010, an allogeneic CAR-T cell therapy. A 100% complete response (CR) rate was observed in six patients following a single dose, with 40% maintaining CR at six months. The first patient treated remained in CR for 12 months. The trial is now enrolling at a higher dosage, reflecting an initial positive safety profile and clinical activity. Additional data is expected by year-end 2022, suggesting potential advancements in CRISPR-edited therapies.

Caribou Biosciences, Inc. (Nasdaq: CRBU) will present additional clinical data from its ANTLER Phase 1 trial of CB-010, a CRISPR-edited CAR-T cell therapy for relapsed/refractory B cell non-Hodgkin lymphoma, during a webcast on June 10, 2022. The presentation will feature longer duration data from six patients treated at dose level 1. The live webcast begins at 8:00 am ET, and the poster will be showcased at the European Hematology Association 2022 Congress in Vienna. CB-010 represents a novel approach with a PD-1 knockout design aimed at enhancing antitumor activity.

Caribou Biosciences (Nasdaq: CRBU) presented studies at the 25th Annual Meeting of the American Society for Gene and Cell Therapy (ASGCT) on May 16, 2022, showcasing the enhanced specificity of its CRISPR hybrid RNA-DNA (chRDNA) guides for genome editing. Dr. Steve Kanner highlighted that these guides improve the efficacy and persistence of allogeneic cell therapies by minimizing off-target activities. The optimized chRDNA guides demonstrate superior precision in editing primary human T cells, reinforcing their potential in therapeutic applications.

Caribou Biosciences (Nasdaq: CRBU) reported significant initial results from its ANTLER Phase 1 trial for CB-010, showing a 100% overall response rate (ORR) and 80% complete response rate (CR) in patients with relapsed or refractory B-cell non-Hodgkin lymphoma. The trial treated 5 evaluable patients, all responding positively. CB-010 is notable as the first allogeneic CAR-T cell therapy with a PD-1 knockout, enhancing potential treatment efficacy. Data will be shared at the upcoming European Hematology Association Congress, with ongoing enrollment at a higher dose level planned.

Caribou Biosciences has appointed David L. Johnson to its board of directors, enhancing its leadership as its pipeline of genome-edited cell therapies advances. With 30 years of experience, Johnson previously led global commercial efforts at Global Blood Therapeutics and held significant roles at Gilead Sciences. His expertise in building commercial infrastructure is expected to aid Caribou's progress, particularly in allogeneic cell therapies.

Caribou Biosciences (CRBU) reported financial results for Q1 2022, highlighting a cash position of $390.8 million. The company continues to advance its clinical pipeline with initial data from the ANTLER Phase 1 trial of CB-010 expected at the EHA 2022 Hybrid Congress. Plans include submitting an IND application for CB-011 in H2 2022 and ongoing research in allogeneic CAR-T and CAR-NK cell therapies. Revenues increased to $2.7 million, while R&D and G&A expenses rose significantly, contributing to a net loss of $19.1 million.

Caribou Biosciences (Nasdaq: CRBU) has announced that CEO Rachel Haurwitz will participate in the BofA Securities 2022 Healthcare Conference on Tuesday, May 10, at 8:00 am PT. The event will feature a fireside chat and will be available for live streaming on Caribou's website, with an archived version accessible for 30 days post-event. Caribou is focused on developing advanced CRISPR-based therapies for severe diseases, utilizing its proprietary Cas12a chRDNA technology for precise genome editing.

Caribou Biosciences (Nasdaq: CRBU) will present groundbreaking studies at the 25th Annual Meeting of the American Society for Gene and Cell Therapy (ASGCT) from May 16-19, 2022. The studies demonstrate the superior specificity of Caribou’s chRDNA genome-editing technology in primary human T cells. The presentation, titled 'Conformational control of Cas endonucleases by CRISPR hybrid RNA-DNA guides mitigates off-target activity in T cells', is scheduled for May 16 at 5:30 PM EDT. This innovative technology aims to enhance precision in genome editing, addressing potential off-target effects.